Actively Recruiting
Patient Preferences for Primary Immune Thrombocytopenia Treatment Survey Study in US Adults
Led by Novartis Pharmaceuticals · Updated on 2026-10-01
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment preferences among adults with Primary Immune Thrombocytopenia ITP in the United States. This observational study aims to understand what treatment features matter most to patients receiving either first-line or second-line therapies. The study is conducted by Novartis Pharmaceuticals and involves a preference elicitation survey to collect patient perspectives. The study has two stages. The first stage focuses on developing the survey and identifying key treatment attributes relevant to patients. The second stage involves administering the finalized survey to adult participants currently treated for ITP, followed by detailed analysis of the collected data to assess how treatment preferences vary with personal characteristics and risk-benefit trade-offs. Participants will complete a survey capturing their preferences related to ITP treatment options. Researchers will analyze preference weights for treatment attributes, acceptable risks, and benefits for each participant. The study involves no drug administration or medical intervention and will last from December 2025 to December 2026. Data collection and analysis aim to provide insights into patient-centered treatment decision-making for ITP.
CONDITIONS
Brief Title
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here